Royal Bank of Canada
TGTX icon

Royal Bank of Canada’s TG Therapeutics TGTX Stock Holding History

Royal Bank of Canada’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,200
Closed -$10K – 7105
2019
Q2 		$10K Buy
+1,200
New +$9.07K ﹤0.01% 6033

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Royal Bank of Canada's TGTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its TG Therapeutics (TGTX) stake by 11% in Q1 2026, selling an estimated $137K and leaving 37,252 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3458.

Royal Bank of Canada first reported a position in TGTX in Q3 2013 and has held it in 46 quarters since. The position peaked at $24.2M in Q2 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Royal Bank of Canada held 37,252 shares of TG Therapeutics worth $1.24M as of Q1 2026.
  • Royal Bank of Canada sold 4,582 TG Therapeutics shares in Q1 2026, an estimated $137K.
  • TG Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3458 holding.
  • Royal Bank of Canada first reported a position in TG Therapeutics in Q3 2013 and has held it in 46 quarters since.
  • Royal Bank of Canada's TG Therapeutics position peaked at $24.2M in Q2 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.